47 results about "N methylglucamine" patented technology

An injectable composition comprises a benzimidazole compound having an antiulcer action and a strong alkali (e.g., an alkali metal hydroxide such as sodium hydroxide) in a proportion of about 1 equivalent of the latter relative to 1 mol of the former, and is substantially free from a nonaqueous solvent. The injectable composition may comprise N-methylglucamine, and a saccharide (such as mannitol). The injectable composition may be a freeze-dried preparation. The freeze-dried preparation is dissolvable in or dilutive with a distilled water for injection or an infusion solution without a nonaqueous solvent. The injectable composition is useful as an antiulcer agent.

An injectable composition comprises a benzimidazole compound having an antiulcer action and a strong alkali (e.g., an alkali metal hydroxide such as sodium hydroxide) in a proportion of about 1 equivalent of the latter relative to 1 mol of the former, and is substantially free from a nonaqueous solvent. The injectable composition may comprise N-methylglucamine, and a saccharide (such as mannitol). The injectable composition may be a freeze-dried preparation. The freeze-dried preparation is dissolvable in or dilutive with a distilled water for injection or an infusion solution without a nonaqueous solvent. The injectable composition is useful as an antiulcer agent.

The present invention discloses a powder injection for intravenous injection for curing several diseases of liver damage with obvious therapeutic effect. Said powder injection has the action of protecting liver, its main component is silibinin-N-methylglucamine whose content is 20-500 mg / g.

This invention pertains to pharmaceutical compositions comprising certain carbamic acid compounds (e.g., which inhibit HDAC (histone deacetylase) activity) (e.g., PXD-101, N hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide)) and one or more additional ingredients selected from cyclodextrin, arginine, and meglumine. The present invention also pertains to the use of such compositions, for example, in the inhibition of HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.

The invention relates to a preparation method of a medicinal preparation of repaglinide. The preparation method comprises the following steps: (a) dissolving meglumine and repaglinide in alcohol and water to prepare an adhesive solution; (b) mixing pharmaceutically acceptable adjuvant materials to prepare a mixture; (c) adding the adhesive solution to the mixture obtained in the step b, and performing wet granulation; and (d) preparing the medicinal preparation. The invention further relates to application of meglumine as a repaglinide stabilizer in the medicinal preparation containing repaglinide.

The invention relates to the field of pharmaceutical, in particular a novel process for preparation of silybum mariamum extractive methylglucamine, wherein dissolvent method is employed for preparing silybum mariamum extractive methylglucamine from silybum marianum extract at nonrefluence state, compared with the prior art, this method eliminates heating backflow, dissolvent decompression reclamation and long period of decompression drying, the content of silibinin-N-methylglucamine is over 99.0%.

The invention discloses rheinic acid derivatives and treatment application thereof, belonging to the field of medicine. A compound with a bioactivity is a compound as shown in a general formula (I) or salts, solvates or hydrates thereof, wherein X3 is the residue of the compound with the bioactivity, and X1 and X2 are independently H or acetyl individually; X3 is the residue of ligustrazine, arginine, lysine or carnitine; X3 is the residue of meglumine, glucosamine or glucose; and X3 is the residue of meglumine, glucosamine or glucose acetylate. The treatment application is as follows: the rheinic acid derivatives can be used for preparation of medicaments for treating or preventing heart cerebrovascular diseases, and can also be used for preparation of medicaments for treating or preventing diseases related to T-cell proliferation or diseases mediated by pro-inflammatory cytokines.

The invention relates to a medicament for treating acute and chronic hepatitis and process for preparation, wherein the medicament is prepared from silibinin-N-methylglucamine as the main constituent, and right mxtrix through a predetermined processing combinations. Compared with the existing dosage forms, the drop pill preparation has the advantages of short technological process, low cost of production and quick-effectiveness.

The present invention is one kind compound Chinese medicine preparation for protecting liver and treating various hepatopathy and its preparation process and quality control method. The compound preparation consists of water soluble silybin derivative silybin meglumine and total arasaponin as the effective components of notoginseng in the weight ratio of 1 to 0.2-2. It is prepared into injection through dissolving, adding polyglycol or propylene glycol as co-solvent, filtering, ultrafiltering and packing; or into powder for injection through dissolving, adding mannitol or glucose as forming agent, filtering, ultrafiltering and freeze drying. Its contents of silybin and total arasaponin and its fingerprint are determined via HPLC process. The compound preparation of the present invention has curative effect obviously higher than its single components, and has the features of high curative effect and high safety.

The invention relates to stable lornoxicam solution and a preparation method and an application thereof; the solution contains the lornoxicam or the pharmaceutically-acceptable salt of the lornoxicam, meglumine, potassium phosphate salt and / or sodium phosphate salt, and has the advantages of good solubility, good stability and good security. The solution of the invention is suitable for parenteral administration such as intramuscular injection, intravenous injection or ophthalmic purpose; the solution which is suitable for the invention is selected from injection preparation, lyophilization formulation or spraying desiccant, preferably the lyophilization formulation.

The invention relates to a silymarin meglumine inclusion compound, which is prepared form hepadestal aminomethane and different materials through enclosing technology, the invention also discloses a Silymarin Methylglucamine clathrate compound preparation method.

The invention belongs to the technical field of energy conservation and environmental protection, and particularly relates to a method for recycling germanium from a germanium-containing solution andthe application of the method. The method comprises the following steps that germanium is selectively adsorbed in the germanium-containing solution under an alkaline condition by adopting anion exchange resin containing a meglumine functional group, and germanium desorption is carried out on anion resin loaded with germanium anions under an acidic condition to obtain a primarily enriched germanium-containing acidic solution; the pH value of the germanium-containing acidic solution is adjusted to be alkaline, the germanium in the solution is adsorbed and precipitated by using a nano alkaline-earth metal oxide, and the precipitate is dried to obtain germanium-containing concentrate; and the germanium-containing concentrate is subjected to chlorination distillation to obtain germanium tetrachloride, germanium dioxide is obtained through hydrolysis, and thus germanium recycling is achieved. The method realizes selective adsorption of germanium in the germanium-containing solution, efficient enrichment and low-cost resource recycling can be realized, the problems of high cost, large acid consumption, environmental unfriendliness and the like of traditional tannin germanium precipitation, neutralization precipitation, chlorination distillation and other processes can be effectively solved, and the method has the characteristics of simple process, low cost, environmental friendlinessand the like.

The invention relates to a meglumine production process which comprises the following steps: S1, condensing monomethylamine with glucose in absolute ethyl alcohol to obtain a Schiff's salt; s2, addinga catalyst and absolute ethyl alcohol into the Schiff's salt, introducing hydrogen to react to obtain hydride, performing crystallizing to obtain solid hydride, adding water to melt the hydride, adding disodium ethylene diamine tetraacetate, carrying out concentrating under reduced pressure, carrying out centrifugal filtration to obtain a meglumine crude product, and purifying the meglumine crudeproduct, wherein the catalyst is skeleton nickel, and the preparation method of the skeleton nickel comprises the following steps: stirring liquid caustic soda, performing heating to 40-47 DEG C, gradually adding aluminum-nickel-chromium-rhodium alloy powder, naturally performing heating to 85-100 DEG C, keeping the temperature for 2.5-3 hours, performing cooling to 55-65 DEG C, stopping stirring, and performing washing with water and absolute ethyl alcohol. The meglumine production process has the effect of improving the meglumine production efficiency.

The invention discloses a medicine composition containing cefpodoxime proxetil. Meglumine is added into the composition to be used as a gelatin inhibitor; the gelation phenomenon of the solid preparation in an aqueous solution can be effectively inhibited; the dissolution-out performance of a solid preparation is effectively improved; the bioavailability is further improved. A flavoring agent of sodium glutamate is added in the composition to achieve the cooperated effect with meglumine, the problem of bitter taste of the particle preparation is solved. Through a dry process granulation process, the introduction of adverse factors such as moisture and high temperature is avoided; a preparation recipe is matched; the problems of hydrolysis or oxidization degradation of ester bonds, amido bonds, lactam bonds and primary amine groups in raw medicine molecules is solved. Experiments prove that the effect is good.

The invention relates to an adenosine cyclophosphate double-molecule meglumine compound and a preparation method thereof, and provides a compound formed by 1 molecule of adenosine cyclophosphate and 2 molecules of meglumine, a preparation method thereof and a medicinal composition comprising the denosine cyclophosphate double-molecule meglumine compound. The water solubility and the stability of the compound are more excellent than those of the conventional compounds.

The invention discloses a lymphocyte separating medium and a preparation method thereof, the lymphocyte separating medium is characterized by comprising the following components: glycerin, ethanol, sucrose, meglumine, diatrizoic acid and epichlorohydrin; the sucrose and the diatrizoic acid are added into an ethanol solution to synthesize a water-soluble polysucrose ethanol solution as a molecular sieve separating medium; the method also includes adding meglumine and epichlorohydrin into glycerol, preparing a clear biological solution at room temperature, putting the biological solution into a dialysis paper bag, putting the dialysis paper bag into deionized water, carrying out ion replacement culture for a period of time, and detecting that the dialysis paper bag does not contain redundant foreign ions; then adjusting the pH value of the two solutions to a proper range by using sodium hydroxide and hydrochloric acid; finally, mixing and stirring the two solutions with the pH value adjusted to be stable to be uniform, and obtaining the lymph separation medium. The lymphocyte separation efficiency is high, the separation purity is high, the quality of lymphocytes is improved, high-quality lymphocytes can be obtained, and the lymphocyte separation medium is suitable for clinical application and popularization.

The invention relates to a meglumine production process capable of recycling a solvent. The meglumine production process comprises the following steps: S1, condensing monomethylamine with glucose in absolute ethyl alcohol to obtain a Schiff's salt; S2, adding a catalyst and absolute ethyl alcohol into the Schiff's salt, introducing hydrogen for a reaction to obtain hydride, conducting crystallizing to obtain solid hydride and mother liquor, separating the solid hydride, melting the hydride, adding disodium ethylene diamine tetraacetate, conducting concentrating under reduced pressure, and carrying out centrifugal filtration to obtain a crude meglumine product; S3, recrystallizing the crude meglumine product in methanol to obtain a methanol mother solution and a wet meglumine product, and distilling the methanol mother solution under reduced pressure to obtain a methanol recovery solution; and S4, adding sulfuric acid into the mother solution obtained in the step S2 to adjust a pH value to 6-7, adding silica gel particles, continuously conducting stirring and uniform mixing, filtering out the silica gel particles to obtain a filtrate, and conducting distilling to obtain an ethanol recovery solution. The process of the invention has the effect of improving ethanol recovery and dehydration effect.

The invention provides a preparation process and a purification process of gadadotec acid meglumine. The preparation process comprises the steps of adding purified DOTA into pure water, stirring and dissolving at room temperature, adding gadolinium oxide and microporous calcium silicate particles, adding meglumine until the pH value of the solution is 7-9, carrying out ultrasonic oscillation, filtering, heating the filtrate to the temperature of 40-50 DEG C, stirring, reacting for 2-4 hours, filtering the precipitate, and performing vacuum drying to obtain the product. The purification method provided by the invention comprises the steps of dissolving a crude product gadadotec acid meglumine in 100ml of methanol, heating while stirring until the gadadotec acid meglumine is dissolved, adding 50ml of water while stirring, stopping stirring, naturally cooling, slowly separating out fine crystals, cooling to the temperature of 5-10 DEG C after 3 hours, adding 30ml of water while stirring, stopping stirring after adding, standing for crystallization, and carrying out suction filtration on the separated white crystals, washing with a small amount of methanol, and carrying out vacuum drying at the temperature of 60 DEG C to obtain crystalline powder.

The present invention relates to a compound which is (R)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydropyrido[2,3-f][1,4]oxazepin-4(5H)-yl)methyl)-4-methylphenyl)propanoic acid (I), or a pharmaceutically acceptable salt thereof, in particular, the meglumine salt thereof, a pharmaceutical composition containing the compound and its use as an NRF2 activator.

The invention provides a crocetin solid dispersion and a preparation method thereof. The formula of the crocetin solid dispersion is as follows: 1 part of insoluble drug crocetin, 1-15 parts of a hydrophilic polymer carrier material, 1-12 parts of solubilizing agent meglumine; the preparation method of the described solid dispersion, the steps are as follows: take the hydrophilic polymer carrier material and meglumine, dissolve them in organic reagents or water, ultrasonically or stir to make the hydrophilic The polymer material and meglumine are cross-linked to form a carrier polymer I, adding crocetin acid to the above solution containing carrier polymer I, ultrasonically or stirring to dissolve the crocetin acid, and using solvent evaporation or spray drying method to prepare solid dispersions. The crocetin solid dispersion prepared by the invention has good solubility and stability, rapid absorption in the body, high bioavailability, simple preparation process and is suitable for industrial production.

The invention relates to the pharmaceutical industry and to medicine, and more particularly to complex polyionic infusion solutions that have a detoxifying effect as a result of antihypoxic, antioxidant and hepatoprotective properties. A preparation can be used to treat intoxications of various origins. The present polyionic infusion solution comprises chlorides of sodium, potassium and magnesium,meglumine sodium succinate as a biologically active component, and water for injection, and also a stabilising agent which is a pharmaceutically acceptable carboxylic acid or inorganic acid or a combination thereof, wherein the solution has a pH from 7.0 to 5.5.

The invention discloses a compound preparation for reducing hepatotoxicity of tripterygium glycoside tablets, and a preparation method of the compound preparation. The compound preparation comprises silibin meglumine tablets and the tripterygium glycoside tablets. The compound preparation has the efficacies of protecting the liver for detoxification, tonifying the kidney and strengthening the spleen; the dosage of tripterygium glycosides can be obviously increased; a better curative effect is achieved; and meanwhile, the hepatotoxicity of the tripterygium glycosides is obviously reduced. In addition, according to the compound preparation, the fast release of silibin meglumine and the long-acting stable release of tripterygium glycosides can be realized, and the treatment effect is furtherimproved. In addition, the preparation method provided by the invention has the advantages that the operation is simple; the cost is low; the preparation method is suitable for industrial production;and the application prospects are good.

The present invention relates to an improved process for the preparation of 1-deoxy-1-methylamino-D- glucitol 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate, also known as tafamidis meglumine. The process of the present invention is particularly suitable for industrial scale manufacture of tafamidis meglumine with excellent purity and high yields.

The invention discloses a preparation method of a silymarin skin care product. The preparation method comprises the following steps: dissolving the silymarin and meglumine in absolute ethyl alcohol, heating the mixture and then recovering the absolute ethyl alcohol, thereby obtaining a silymarin-meglumine raw material; and evenly mixing the silymarin-meglumine raw material with deionized water, placing the mixture in a stirrer, stirring the mixture, adding gelatin and glycerol, further stirring the mixture, adding sodium benzoate and carrying out an ultrasonic processing, thereby obtaining thedesired silymarin skin care product. The invention solves the defects that the traditional preparation method directly adopts the silymarin to prepare related skin care products, resulting in excessive facial skin grease and pore blockage after long-term use; and the silymarin-meglumine and the sodium benzoate are uniformly distributed in other matrixes by ultrasonic even-mixing technology, and the silymarin-meglumine can not be decomposed or damaged.

The invention discloses a synthesis method of fosaprepitant dimeglumine, and belongs to the technical field of medicines. The synthesis method of fosaprepitant dimeglumine mainly comprises the following steps: reacting tetrabenzyl pyrophosphate, adsorbing impurity tar, hydrogenating palladium mesoporous carbon, refining and the like. According to the invention, a one-pot reaction is adopted; a dibenzyl ester product is generated; sodium carbonate is added for quenching reaction, mesoporous carbon is added for adsorbing impurities and tar, palladium-carbon catalyst deactivation is avoided, thena tetrahydrofuran system is directly utilized for a reaction, palladium mesoporous carbon has high activity and can generate monobenzyl ester first and then remove groups through hydrogenation compared with a common route, steps are saved, and high yield is achieved.

The invention provides a magnetic resonance contrast agent as well as a preparation method and application thereof, and relates to the field of magnetic resonance contrast agents. The magnetic resonance contrast agent disclosed by the invention is prepared from a compound with structural characteristics of a formula I shown in the description. The magnetic resonance contrast agent disclosed by the invention can also be a compound with structural characteristics shown as a formula II or pharmaceutically acceptable salt thereof, M1 is a +2 ion of paramagnetic metal Mn, Fe, Eu or Dy, or a +3 ion of Mn, Fe, Eu or Dy; M2 is Na < + >, K < + > or meglumine cation; when M1 is a +2 valence ion, a is equal to 2; and when M1 is a + 3 valence ion, a is equal to 3. The magnetic resonance contrast agent has the characteristics of good water solubility, high relaxation efficiency, low toxic and side effects and the like.